These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15334183)

  • 1. Molecule of the month. Torcetrapib.
    Drug News Perspect; 2004 Jun; 17(5):334. PubMed ID: 15334183
    [No Abstract]   [Full Text] [Related]  

  • 2. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
    Clark RW
    Curr Opin Pharmacol; 2006 Apr; 6(2):162-8. PubMed ID: 16487747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Torcetrapib and atorvastatin--should marketing drive the research agenda?
    Avorn J
    N Engl J Med; 2005 Jun; 352(25):2573-6. PubMed ID: 15972861
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians.
    Forrester JS; Makkar R; Shah PK
    Circulation; 2005 Apr; 111(14):1847-54. PubMed ID: 15824213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
    Zhao L; Jin W; Rader D; Packard C; Feuerstein G
    Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease.
    Brewer HB
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):387-91. PubMed ID: 15003970
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
    McKenney JM; Davidson MH; Shear CL; Revkin JH
    J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.
    Gauthier A; Lau P; Zha X; Milne R; McPherson R
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2177-84. PubMed ID: 16123327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
    Davidson MH; McKenney JM; Shear CL; Revkin JH
    J Am Coll Cardiol; 2006 Nov; 48(9):1774-81. PubMed ID: 17084249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
    Kuivenhoven JA; de Grooth GJ; Kawamura H; Klerkx AH; Wilhelm F; Trip MD; Kastelein JJ
    Am J Cardiol; 2005 May; 95(9):1085-8. PubMed ID: 15842977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raising HDL. In search of more 'good' cholesterol.
    Mayo Clin Health Lett; 2005 Jan; 23(1):7. PubMed ID: 15795960
    [No Abstract]   [Full Text] [Related]  

  • 13. Cholesteryl ester transfer protein and coronary artery disease: an observation with therapeutic implications.
    Wolfe ML; Rader DJ
    Circulation; 2004 Sep; 110(11):1338-40. PubMed ID: 15364817
    [No Abstract]   [Full Text] [Related]  

  • 14. Raising HDL cholesterol.
    Melnikova I
    Nat Rev Drug Discov; 2005 Mar; 4(3):185-6. PubMed ID: 15770778
    [No Abstract]   [Full Text] [Related]  

  • 15. Torcetrapib as potential treatment of low high-density lipoprotein cholesterol: no longer a pipe dream?
    Ahmed MH
    Diabetes Technol Ther; 2008 Aug; 10(4):328-9. PubMed ID: 18715207
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease.
    Sikorski JA
    J Med Chem; 2006 Jan; 49(1):1-22. PubMed ID: 16392785
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.
    Yvan-Charvet L; Matsuura F; Wang N; Bamberger MJ; Nguyen T; Rinninger F; Jiang XC; Shear CL; Tall AR
    Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1132-8. PubMed ID: 17322101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from torcetrapib: putting patient-oriented evidence first.
    Ewart RM
    Am Fam Physician; 2008 Mar; 77(5):597-8. PubMed ID: 18350757
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.